SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, D.D. | - |
dc.contributor.author | Parveen, A. | - |
dc.contributor.author | Yadav, D.K. | - |
dc.date.accessioned | 2022-01-10T23:40:42Z | - |
dc.date.available | 2022-01-10T23:40:42Z | - |
dc.date.created | 2022-01-06 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 2235-2988 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83226 | - |
dc.description.abstract | The emergence of SARS-CoV-2 variants may cause resistance at the immunity level against current vaccines. Some emergent new variants have increased transmissibility, infectivity, hospitalization, and mortality. Since the administration of the first SARS-CoV-2 vaccine to a human in March 2020, there is an ongoing global race against SARS-CoV-2 to control the current pandemic situation. Spike (S) glycoprotein of SARS-CoV-2 is the main target for current vaccine development, which can neutralize the infection. Companies and academic institutions have developed vaccines based on the S glycoprotein, as well as its antigenic domains and epitopes, which have been proven effective in generating neutralizing antibodies. The effectiveness of SARS-CoV-2 vaccines and other therapeutics developments are limited by the new emergent variants at the global level. We have discussed the emergent variants of SARS-CoV-2 on the efficacy of developed vaccines. Presently, most of the vaccines have been tremendously effective in severe diseases. However, there are still noteworthy challenges in certifying impartial vaccines; the stories of re-infections are generating more stressful conditions, and this needs further clinical evaluation. Copyright © 2021 Singh, Parveen and Yadav. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Frontiers Media S.A. | - |
dc.relation.isPartOf | Frontiers in Cellular and Infection Microbiology | - |
dc.title | SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000738678800001 | - |
dc.identifier.doi | 10.3389/fcimb.2021.777212 | - |
dc.identifier.bibliographicCitation | Frontiers in Cellular and Infection Microbiology, v.11 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85121976192 | - |
dc.citation.title | Frontiers in Cellular and Infection Microbiology | - |
dc.citation.volume | 11 | - |
dc.contributor.affiliatedAuthor | Parveen, A. | - |
dc.contributor.affiliatedAuthor | Yadav, D.K. | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | infectivity | - |
dc.subject.keywordAuthor | neutralization | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | vaccine | - |
dc.subject.keywordAuthor | variant | - |
dc.subject.keywordPlus | COVID-19 VACCINE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | B.1.1.7 | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.